In a recent paper published in the Journal of Managed Care and Specialty Pharmacy, Karam Diaby, Ph.D., M.Sc., an assistant professor of pharmaceutical outcomes and policy, and team conducted a cost-effectiveness analysis of comprehensive medication therapy management, or MTM, integrated with genotype-guided antiplatelet therapy selection for U.S. elderly patients after percutaneous coronary intervention. A decision analytic model (combination of decision tree and Markov model) was used to simulate and compare the cost and effectiveness associated with treatment strategies. These strategies included genotype-guided antiplatelet therapy selection (POCP), MTM and genotype-guided antiplatelet therapy selection, MTM and universal clopidogrel, and MTM and universal ticagrelor. Data used to populate the model were obtained from the PLATO trial and other published studies. The authors found that the combination of MTM-ticagrelor was cost-effective when compared with MTM-POCP or MTM-clopidogrel. Diaby and co-authors are planning on replicating this study using observational data as a mean of validation.